Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanosphere IPO Will Fund Development Of Verigene Genomic, Protein Assays

This article was originally published in The Pink Sheet Daily

Executive Summary

Molecular diagnostics firm Nanosphere plans to market its workstation initially for use in testing patients for excessive blood clotting and warfarin metabolism.

You may also be interested in...



Mobile Health Apps Could Disrupt Medical Technology Market– Report

Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.

Mobile Health Apps Could Disrupt Medical Technology Market– Report

Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.

J&J’s Sedasys Sedation System Now “Approvable,” Though Some Questions Remain

Outstanding FDA questions pertain to follow-up data, user training and “post-market observance and those sorts of things,” CFO Dominic Caruso told investors during the firm’s first-quarter earnings call April 17.

Topics

UsernamePublicRestriction

Register

PS066490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel